Tailored hormonal therapy in secretory adrenocortical cancer

Ann Oncol. 2007 Jul;18(7):1281. doi: 10.1093/annonc/mdm273.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adrenal Cortex Neoplasms / complications
  • Adrenal Cortex Neoplasms / drug therapy*
  • Adrenal Cortex Neoplasms / surgery
  • Adrenalectomy
  • Adrenocortical Carcinoma / complications
  • Adrenocortical Carcinoma / drug therapy*
  • Adrenocortical Carcinoma / surgery
  • Aged
  • Aldosterone / blood
  • Alkalosis / chemically induced
  • Alkalosis / drug therapy
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use
  • Anti-Inflammatory Agents / therapeutic use
  • Antifungal Agents / therapeutic use
  • Antineoplastic Agents, Hormonal / adverse effects*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Captopril / therapeutic use
  • Cisplatin / administration & dosage
  • Diarrhea / etiology
  • Doxorubicin / administration & dosage
  • Etoposide / administration & dosage
  • Female
  • Heart Failure / etiology
  • Humans
  • Hydrocortisone / therapeutic use
  • Hyperaldosteronism / etiology
  • Hyperaldosteronism / physiopathology
  • Hypertension / etiology
  • Hypokalemia / chemically induced
  • Hypokalemia / drug therapy
  • Ketoconazole / therapeutic use
  • Mineralocorticoid Receptor Antagonists / therapeutic use
  • Mitotane / adverse effects*
  • Neoplasm Recurrence, Local / drug therapy*
  • Potassium / therapeutic use
  • Rhabdomyolysis / etiology
  • Spironolactone / therapeutic use
  • Tachycardia / etiology

Substances

  • Angiotensin-Converting Enzyme Inhibitors
  • Anti-Inflammatory Agents
  • Antifungal Agents
  • Antineoplastic Agents, Hormonal
  • Mineralocorticoid Receptor Antagonists
  • Spironolactone
  • Aldosterone
  • Etoposide
  • Mitotane
  • Doxorubicin
  • Captopril
  • Cisplatin
  • Ketoconazole
  • Potassium
  • Hydrocortisone